Prenatal Exposure to Polycyclic Aromatic Hydrocarbons, Benzo[a]pyrene–DNA Adducts, and Genomic DNA Methylation in Cord Blood by Herbstman, Julie B. et al.
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 5 | May 2012  733
Research | Children’s Health
Polycyclic aromatic hydrocarbons (PAHs) are 
carcinogenic environmental pollutants result-
ing from incomplete combustion that are 
commonly found in tobacco smoke, ambient 
and indoor air, and charbroiled foods. After 
exposure, these compounds are metabolized 
to form phenolic products and reactive epox-
ides, which have the capacity to bind to DNA, 
forming PAH–DNA adducts (Whyatt et al. 
1998). PAH–DNA adducts increase the likeli-
hood of gene mutations and have been associ-
ated with various forms of cancer (Kriek et al. 
1998). PAHs can cross the placenta, and previ-
ous studies have suggested that the developing 
fetus may be 10 times more susceptible than 
the mother to PAH-induced DNA damage 
(Perera et al. 2005).
PAH exposure has also been associated 
with epigenetic alterations, including genomic 
cytosine methylation. Benzo[a]pyrene (BaP), 
a five-ring mutagenic PAH, has been shown 
to disrupt DNA methylation patterns in 
experimental systems (Sadikovic et al. 2007; 
Wilson and Jones 1983). Additionally, global 
DNA hypomethylation is associated with 
genome instability and subsequent cancer risk 
(Hoffmann and Schulz 2005; Wilson et al. 
2007). Early embryonic development may be 
a particularly susceptible period for epigenetic 
dysregulation as a consequence of environmen-
tal exposures, because DNA synthesis rates are 
high and DNA methylation patterns are being 
established (Dolinoy et al. 2007).
Prenatal exposure to PAHs may result in 
both increased PAH–DNA adducts and altered 
DNA methylation, and both mechanisms have 
been associated with increased cancer risk 
(Pfeifer 2006). In addition, experimental stud-
ies suggest that PAH-induced DNA adducts 
may preferentially form at guanine residues 
near methylated cytosines (Chen et al. 1998; 
Denissenko et al. 1996; Tretyakova et al. 2002; 
Weisenberger and Romano 1999).
In this epidemiologic study, we sought to 
determine whether prenatal exposure to PAHs 
is associated with altered global methylation in 
umbilical cord white blood cells (WBCs) and 
to determine whether methylation is associ-
ated with the presence of detectable PAH–
DNA adducts.
Materials and Methods
Study design. The Columbia Children’s 
Center for Environmental Health (CCCEH) 
Northern Manhattan Mothers and Newborns 
Study is a longitudinal cohort study com-
prising African-American and Dominican 
women who were recruited in the prenatal 
clinics of New York Presbyterian Medical 
Center, Harlem Hospital, or their satellite 
clinics, as previously described (Perera et al. 
2002). Eligible women included those who 
did not smoke or use illicit drugs; were 18–35 
years of age at time of delivery; registered in 
the prenatal clinics by the 20th week of preg-
nancy; were free of diabetes, hypertension, 
and reported HIV infection; and had resided 
in northern Manhattan or the South Bronx 
neighborhoods of New York City for at least 
1 year. Eligible women who gave informed 
consent were considered “initially enrolled.” 
Women who completed 48-hr personal pre-
natal air monitoring during the third trimester 
of pregnancy and the collection of maternal 
and/or umbilical cord blood were considered 
“fully enrolled” (Perera et al. 2003).
For this study, we randomly selected 
164 participants from the CCCEH cohort 
of 725 women with stored cord blood DNA, 
half with prenatal PAH exposure levels above 
and half with exposures below the population 
median (PAHs, including pyrene, 5.314 ng/m3; 
PAHs, not including pyrene, 2.265 ng/m3). 
In addition to PAH exposure, we considered 
PAH-urinary metabolites and BaP–DNA 
adducts as indicators of internal dose and bio-
logically effective dose, respectively (Figure 1).
Prenatal personal PAH assessment. 
During the third trimester of pregnancy, per-
sonal monitoring was carried out as previ-
ously described (Perera et al. 2003, 2006). 
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Ba c k g r o u n d: Polycyclic aromatic hydrocarbons (PAHs) are carcinogenic environmental pollutants 
generated during incomplete combustion. After exposure and during metabolism, PAHs can form 
reactive epoxides that can covalently bind to DNA. These PAH–DNA adducts are established mark­
ers of cancer risk. PAH exposure has been associated with epigenetic alterations, including genomic 
cytosine methylation. Both global hypomethylation and hypermethylation of specific genes have 
been associated with cancer and other diseases in humans. Experimental evidence suggests that 
PAH–DNA adduct formation may preferentially target methylated genomic regions. Early embry­
onic development may be a particularly susceptible period for PAH exposure, resulting in both 
increased PAH–DNA adducts and altered DNA methylation. 
oB j e c t i v e: We explored whether prenatal exposure to PAHs is associated with genomic DNA 
methylation in cord blood and whether methylation levels are associated with the presence of 
detectable PAH–DNA adducts.
Me t h o d s : In a longitudinal cohort study of non  smoking women in New York City, we measured 
PAH exposure during pregnancy using personal air monitors, assessed PAH internal dose using pre­
natal urinary metabolites (in a subset), and quantified benzo[a]pyrene–DNA adducts and genomic 
DNA methylation in cord blood DNA among 164 participants.
re s u l t s: Prenatal PAH exposure was associated with lower global methylation in umbilical cord 
white blood cells (p = 0.05), but global methylation levels were positively associated with the pres­
ence of detectable adducts in cord blood (p = 0.01). 
co n c l u s i o n s: These observations suggest that PAH exposure was adequate to alter global methyla­
tion in our study population. Additional epidemiologic studies that can measure site­specific cytosine 
methylation and adduct formation will improve our ability to understand this complex molecular 
pathway in vivo.
key w o r d s : adducts, epigenetics, methylation, polycyclic aromatic hydrocarbons, prenatal, 
umbilical cord blood. Environ Health Perspect 120:733–738 (2012).  http://dx.doi.org/10.1289/
ehp.1104056 [Online 17 January 2012]Herbstman et al.
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Vapors and particles ≤ 2.5 μg in diameter were 
collected on a precleaned quartz microfiber 
filter and a precleaned polyurethane foam car-
tridge backup. The samples were analyzed at 
Southwest Research Institute (San Antonio, 
TX) for pyrene, benz[a]anthracene, chrysene, 
benzo[b]fluoranthene, benzo[k]fluoranthene, 
BaP, indeno[1,2,3-cd]pyrene, dibenz[a,h]
anthracene, and benzo[g,h,i]perylene as 
described by Tonne et al. (2004). For quality 
control, each personal monitoring result was 
assessed for accuracy in flow rate, time, and 
completeness of documentation. All of the 
164 subjects had samples of acceptable quality.
Measurement of PAH metabolites. We 
measured PAH metabolite levels in the urine 
collected prenatally from a subset of partici-
pants in our present study sample (n = 87). 
The availability of urinary metabolite mea-
surements was dependent on the participant’s 
willingness to donate a urine sample and the 
quantity of urine donated in relation to the 
requirements of the assay. Each subject’s pre-
natal urine sample was analyzed at the Centers 
for Disease Control and Prevention (Atlanta, 
GA) for a suite of 10 PAH metabolites as 
previously described: 2-, 3- and 9-hydroxy-
fluorene, 1- and 2-hydroxynaphthalene, 1-, 
2-, 3-, and 4-hydroxyphenanthrene, and 
1-hydroxypyrene (Li et al. 2006). Analytical 
determination was conducted by using enzy-
matic deconjugation, followed by automated 
liquid–liquid extraction, and quantified by gas 
chromatography/isotope dilution high-resolu-
tion mass spectrometry. The limit of detection 
(LOD) was defined as the higher of either 
the method blank LOD (three times standard 
deviation of method blanks after subtracting 
the average blank) or the instrument LOD 
(lowest point on the calibration curve having a 
signal more than three times the signal-to-noise 
ratio). Values below the LOD were recoded as 
half the LOD. PAH metabolites were detected 
in all samples except 3-hydroxyfluorene (eight 
samples < LOD), 1-hydroxyphenanthrene 
(one < LOD), 3-hydroxy  phenanthrene (two 
< LOD), and 4-hydroxyphenanthrene (three 
< LOD). To control for urine dilution, we 
adjusted metabo  lite concentrations for urine 
specific gravity levels, which were measured 
using a handheld refractometer (model PAL-
10-S-P14643C0 urine specific gravity refrac-
tometer; TAGO USA Inc., Bellevue, WA). 
As described in previous publications, we 
used urinary specific gravity rather than uri-
nary creatinine to account for urinary dilu-
tion, because urinary creatinine may provide a 
biased estimate of dilution in asthmatics (and 
~ 25% of our subjects are asthmatics) (Miller 
et al. 2010).
Analysis of global DNA methylation. DNA 
isolated from umbilical cord blood leuko-
cytes was analyzed for global DNA methyla-
tion using the MethylampTM Global DNA 
Methylation Quantification Kit (Epigentek 
Group Inc., Farmingdale, NY). The assays were 
run on four 96-well plates, and all samples 
(n = 164) were run in duplicate on the same 
plate. This methodology quantifies the methy-
lated fraction of DNA using an ELISA-like 
reaction. The proportion of methylated DNA 
in the full sample is determined by plotting the 
intensity of the optical density generated from 
the reaction compared with the standard curve 
produced using a methylated DNA control. In 
the samples analyzed in this study, the coeffi-
cient of variation between replicates was 16%.
BaP–DNA adducts. BaP–DNA adducts 
were analyzed in umbilical cord blood sam-
ples with sufficient DNA quantities (n = 152, 
93% of the study sample). BaP is widely used 
as a representative PAH because concentra-
tions of individual PAHs in the urban set-
ting are highly correlated; therefore, we used 
BaP–DNA adducts as a proxy for PAH–
DNA adducts (Perera et al. 2004). We ana-
lyzed BaP–DNA adducts in extracted WBC 
DNA using a high-performance liquid 
  chromatography–fluorescence (HPLC-F) 
method, which detects BaP tetrols released 
after hydrolysis of DNA adducts during the 
sample preparation (Alexandrov et al. 1992). 
The method has a coefficient of variation of 
12% and a lower LOD of 0.25 adducts per 108 
nucleotides.
Questionnaire-based information. We 
obtained information about demographic 
characteristics based on responses to an inter-
viewer-administered questionnaire at baseline 
during prenatal visits. In addition, we used 
questionnaire-based information to estimate 
dietary exposure to PAHs by quantifying the 
consumption of smoked, fried, broiled, and 
barbecued meats. We also estimated exposure 
to environmental tobacco smoke (ETS) using 
a combination of questionnaire-based infor-
mation (whether or not the mother cohabi-
tated with a smoker during pregnancy) and/or 
whether cotinine levels measured in umbilical 
cord blood > 1 ng/mL (Benowitz et al. 2009).
Statistical analysis. The total PAH level 
in air was calculated as the sum of the eight 
PAHs measured (excluding pyrene). Pyrene 
and BaP in air were analyzed separately. 
Prenatal air PAH levels were natural log 
transformed when modeled as continuous 
variables or were divided at the median for 
categorical analyses. For the DNA methyla-
tion analyses, we used the average of the pro-
portion of methylation generated from the 
duplicate wells, unless the duplicate result 
did not meet our quality assessment and con-
trol criteria. In five cases, we used the pro-
portion of methylation generated from one 
quantifiable well. Genomic methylation was 
natural log transformed. One sample with 
no detectable methylation was assigned the 
lowest measurable methylation value in our 
sample (0.08 ng/100 ng total DNA) divided 
by the square root of 2. BaP–DNA adducts 
were dichotomized as either detectable or 
not detectable; there were 12 participants for 
whom BaP–DNA adduct measurements were 
not available. We used multivariate linear 
regression models to estimate the associations 
between prenatal PAH exposure (measured 
in both air and urine) and methylation. We 
used multivariate logistic regression models 
to estimate the associations between methyla-
tion and the presence or absence of adducts 
and to explore whether methylation alters the 
association between prenatal PAH exposure 
(in air and urine) and the presence of adducts 
(Baron and Kenny 1986). Covariates were 
considered potential confounders if related 
to genomic methylation based on previous 
reports (Terry et al. 2008), including mater-
nal age, ethnicity, marital status, education, 
annual household income, child’s sex, and 
mother’s parity. Covariates were included in 
multivariate models as potential confound-
ers only if they were associated with both 
the independent and dependent variables at 
p < 0.15. In all other cases, an α of 0.05 is 
Figure 1. Conceptual association between exposure measures and biomarkers along the toxicologic 
paradigm. Indicators of exposure include airborne BaP and other PAHs and dietary sources of PAHs. 
Biomarkers of internal dose include 1-OH-pyrene metabolites. Biomarkers of biologically effective dose 
include global DNA methylation and PAH–DNA adducts.
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considered statistically significant. Analyses 
were conducted using STATA/SE (version 
11.0; StataCorp, College Station, TX) and 
the ggplot2 package (Wickham 2009) in R 
(version 2.14.1; R Foundation for Statistical 
Computing, Vienna, Austria).
Results
The distributions of PAH measurements in 
air and urine, BaP–DNA adducts, and DNA 
methylation in our study population are 
described in Table 1. Median BaP and total 
PAH concentrations were 0.24 and 2.47 ng/m3, 
respectively. BaP–DNA adducts were detected 
in half of all participants. DNA methyla-
tion ranged from 0.06 to 5.42 ng/100 ng 
total DNA. Demographic characteristics in 
this study sample were similar to those of the 
underlying cohort (Table 2). Two-thirds of 
the participants were Dominican, and one-
third were African American. Most participants 
were unmarried and had an annual household 
income < $30,000. Consistent with the study 
sample selection criteria, half (49.4%) of the 
study sample had prenatal air PAH levels above 
the population median of 2.3 ng/dL, and half 
(50.6%) had air PAH levels below the median 
(Table 2). The proportion of participants with 
detectable BaP–DNA adducts in this sample 
(50%) was significantly lower than in the 
underlying cohort (67%).
Indicators of PAH exposure. We used air-
borne PAH exposure and PAH urinary metabo-
lites measured in maternal urine collected 
prenatally from a subset of 87 women to esti-
mate prenatal PAH exposure and internal dose, 
respectively. Demographic characteristics were 
not associated with PAH exposure indices, with 
a few exceptions: African Americans were sig-
nificantly more likely than Dominicans to have 
high geometric mean levels of 1-hydroxynaph-
thalene (3117.1 vs. 1497.5 ng/L urine), 
2-hydroxyfluorene (337.1 vs. 231.2 ng/L 
urine), and 4-hydroxyphenanthrene (80.3 vs. 
53.0 ng/L urine). Women with higher income 
had lower levels of 1-hydroxypyrene: Women 
with annual household incomes < $10,000 had 
geometric mean 1-hydroxypyrene concentra-
tion of 187.8 ng/L urine, compared with 137.2 
and 130.2 ng/L urine among women making 
$10,000–30,000 and > $30,000, respectively.
Mothers exposed to ETS during their preg-
nancy were, on average, younger, more likely 
to be African American than Dominican, less 
likely to be married, and more likely to have 
lower annual household income than were 
mothers who were not ETS exposed (data not 
shown). Those with ETS exposure had higher 
levels of 3-hydroxyfluorene (56.2 vs. 37.5 ng/L 
urine, p = 0.04). African Americans tended to 
consume more PAH-containing meats than did 
Dominican participants. However, our index 
of PAHs from smoked, broiled, fried, or bar-
bequed meat was not correlated with any of our 
PAH metabolite measures (r = –0.11 to 0.19).
The total PAH level in air was positively 
correlated with pyrene and BaP (Pearson’s 
r  = 0.69 and 0.96, respectively), and 
individual PAH metabolites were also cor-
related with one another (r = 0.30–0.89). The 
total airborne PAH level was only moderately 
correlated with 2-hydroxyfluorene, 2-, 3-, 
and 4-hydroxyphenanthrene, and 1-hydroxy-
pyrene (r = 0.20–0.26) and was not correlated 
with the other measured PAH metabolites. 
Pyrene in air was moderately correlated with 
all measured metabolites (r = 0.20–0.49), 
except for the naphthalene metabolites.
PAH exposure and DNA methylation. 
Using univariate linear regression, we found 
that cord blood global methylation was lower 
(p < 0.01) among African Americans (geomet-
ric mean = 1.04 ng/100 ng total DNA) than 
among Dominicans (1.35 ng/100 ng total 
DNA). However, no other demographic vari-
ables were significantly associated with global 
methylation levels.
Natural log–transformed methylation 
was negatively associated with the natural 
Table 1. Distribution of PAH exposure in air and urine, BaP–DNA adducts, and DNA methylation in our 
study population.
Percentile Geometric 
mean (GSD) Exposure variable n 5th 25th 50th 75th 95th
PAHs in air (ng/m3)a
Benz[a]anthracene 164 0.05 0.13 0.21 0.40 0.84 0.23 (2.30)
Chrysene 164 0.05 0.15 0.27 0.46 1.09 0.27 (2.39)
Benzo[b]fluoranthene 164 0.11 0.20 0.46 0.85 2.08 0.45 (2.72)
Benzo[k]fluoranthene 164 0.04 0.05 0.10 0.20 0.54 0.11 (2.70)
BaP 164 0.04 0.12 0.24 0.62 1.54 0.27 (3.26)
Indeno[1,2,3-cd]pyrene 164 0.05 0.19 0.41 0.89 2.94 0.41 (3.25)
Dibenz[a,h]anthracene 164 0.02 0.04 0.05 0.06 0.10 0.05 (1.73)
Benzo[g,h,i]perylene 164 0.12 0.34 0.67 1.35 4.66 0.69 (3.27)
Pyrene 164 1.16 1.70 2.62 4.94 11.18 2.98 (2.14)
Total PAHsb 164 0.64 1.28 2.47 5.05 13.53 2.66 (2.71)
PAHs in urine (ng/L urine)b
2-Hydroxyfluorene 87 109.8 176.4 238.9 335.7 879.4 257.6 (1.94)
3-Hydroxyfluorene 87 11.8 27.7 40.8 68.0 167.8 44.6 (2.39)
9-Hydroxyfluorene 87 266.3 408.2 627.5 987.9 1957.0 657.9 (1.96)
1-Hydroxynaphthalene 87 404.9 958.4 1870.2 3048.9 10887.0 1848.7 (2.83)
2-Hydroxynaphthalene 87 961.0 1758.5 2814.3 4573.2 18861.6 3117.3 (2.47)
1-Hydroxyphenanthrene 87 110.6 175.5 251.0 440.5 1029.2 280.9 (1.98)
2-Hydroxyphenanthrene 87 42.2 68.1 110.7 199.1 372.0 118.2 (2.04)
3-Hydroxyphenanthrene 86 28.6 49.0 79.8 152.7 298.8 84.3 (2.17)
4-Hydroxyphenanthrene 83 17.3 33.1 54.1 109.3 261.9 59.8 (2.30)
1-Hydroxypyrene 87 53.9 105.2 154.1 214.6 472.1 152.8 (2.0)
BaP-DNA adducts (adducts/108 nucleotides) 152 ND ND ND 0.34 0.52 0.32 ±1.04c
DNA methylation (ng/100 ng total DNA) 164 0.31 0.93 1.34 1.81 3.28 1.24 (2.00)
Abbreviations: GSD, geometric standard deviation; ND, not detected.
aSum of all PAHs measured (except pyrene). bSpecific gravity adjusted using the following formula: PAH concentration = 
PAHs × [(1.019 – 1)/(Specific gravity – 1)], where constant (1.019) refers to the median specific gravity measure observed 
in this cohort. cMean ± SD.
Table 2. Characteristics of subjects included in 
this analysis and the underlying cohort [n (%)].
Characteristic
Present 
analysis 
(n = 164)
Full cohort 
(n = 727)
Maternal age (years)
< 20 28 (17.1) 121 (16.7)
20–24 64 (39.2) 289 (39.8)
25–29 48 (29.3) 176 (24.2)
≥ 30 24 (14.6) 140 (19.3)
No. missing 0 1
Ethnicity
Dominican 113 (68.9) 473 (65.1)
African American 51 (31.1) 254 (34.9)
No. missing 0 0
Marital status
Not married 126 (77.3) 529 (72.8)
Married/cohabitating 37 (22.7) 194 (26.7)
No. missing 1 4
Maternal education
< High school 46 (28.8) 257 (36.0)
Completed high school 66 (41.2) 285 (40.0)
> High school 48 (30.00) 171 (24.0)
No. missing 4 14
Annual household income
< $10,000 66 (40.7) 303 (42.2)
$10,000–30,000 65 (40.1) 277 (38.6)
> $30,000 31 (19.1) 138 (19.2)
No. missing 2 9
Child sex
Male 83 (50.6) 351 (48.3)
Female 81 (49.4) 376 (51.7)
No. missing 2 9
Parity
Nulliparous 42 (25.6) 175 (24.2)
Multiparous 122 (74.4) 548 (75.8)
No. missing 0 4
Total PAHs
> Median (2.3 ng/m3) 81 (49.4) 344 (49.9)
< Median 83 (50.6) 343 (50.1)
No. missing 0 40
BaP–DNA adductsa
Nondetected 80 (50.0) 218 (33.4)
Detected 80 (50.0) 434 (66.6)
No. missing 4 75
aDifference between study sample and population sample 
significant at p = 0.01.Herbstman et al.
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log of prenatal air PAH exposure [β = –0.11; 
95% confidence interval (CI): –0.21, 0.00; 
p = 0.05]. Associations were similar for pyrene 
(β = –0.18; 95% CI: –0.32, –0.04; p = 0.01) 
and for BaP (–0.09; 95% CI: –0.18, 0.00; 
p = 0.06). Methylation levels among par-
ticipants with BaP, pyrene, and total PAHs 
above the median (“high”) were lower than 
methylation levels among those with BaP, 
pyrene, and total PAHs below the median 
(“low”) (p = 0.08, 0.03, and 0.01, respectively) 
(Figure 2). Participants exposed to prenatal 
ETS had levels of methylation similar to lev-
els in those who were not exposed (1.25 vs. 
1.24 ng/100 ng total DNA, p = 0.90). When 
ethnicity was added to the multivariate linear 
regression models to assess confounding, none 
of these associations (β-coefficients) changed, 
leading us to conclude that the associations 
were not confounded by ethnicity.
Participants with PAH urinary metabolite 
data were similar to the rest of the sample in 
terms of total air PAH concentrations and 
proportion of detectable DNA adducts, but 
they had significantly higher average global 
DNA methylation (geometric mean of 1.00 
vs. 1.51 ng/100 ng DNA, p < 0.01). In this 
subset of participants (n = 87), a slightly 
positive but non  significant association was 
observed between metabolite levels and global 
DNA methylation when two heavily influen-
tial observations were removed (all p-values 
> 0.10) (data not shown).
PAH exposure and BaP–DNA adduct 
  formation. No association was observed between 
any of the covariates presented in Table 2 and 
the presence of BaP–DNA adducts (p > 0.10), 
except for parity: Nulliparous women were less 
likely to have detectable adducts (p = 0.06) than 
were multiparous women. Detectable adducts 
were not associated with any of the PAH expo-
sure indicators, including all measures of air 
exposure, ETS, dietary PAHs from meat, and 
(in the subset for whom they were measured) 
PAH metabolites (data not shown).
DNA methylation and BaP–DNA adduct 
formation. Newborns with detectable cord 
BaP–DNA adducts had higher levels of 
genomic methylation than did those with non-
detectable adducts (odds ratio = 2.35; 95% CI: 
1.35, 4.09; p < 0.01) (Figure 3). None of the 
covariates presented in Table 2 confounded 
this association. In this analysis, global methy-
lation levels did not mediate or modify the 
relationship observed between PAH exposure 
and the presence of detectable adducts.
Discussion
Among African-American and Dominican 
newborns in a New York City birth cohort, 
we found that prenatal exposure to PAHs 
measured using a personal air monitor during 
the third trimester of pregnancy was associated 
with lower global methylation levels measured 
in umbilical cord WBC DNA. We did not 
observe similar associations between PAHs 
and methylation when prenatal PAH exposure 
was estimated by urinary PAH metabolites, 
but the subset of 87 participants for whom we 
had metabolite data may not have provided 
us with adequate statistical power to evaluate 
this association. We also found that higher 
global methylation levels were positively asso-
ciated with the presence of detectable adducts 
in cord blood, but we did not observe associa-
tions between estimates of PAH exposure [esti-
mated using air monitors, questionnaires (diet 
and ETS), or metabolite levels] and detectable 
BaP–DNA adducts.
PAH–DNA adduct levels provide an inte-
grated index of biologically effective dose, 
indicative of both exposure to PAHs from 
all routes (including both inhalation, dermal 
absorption, and ingestion) and individual 
metabolic differences in detoxification (Veglia 
et al. 2008). As we have reported previously 
in this cohort, BaP–DNA adducts were not 
significantly associated with individual mea-
sures of PAH exposure in personal air, nor 
were they related to ETS or an indicator of 
dietary PAHs based on self-reported con-
sumption of foods known to be high in PAHs 
(Perera et al. 2004). In the sample of cohort 
participants we studied here, our results are 
consistent, perhaps because adducts reflect 
individual exposure, susceptibility to adduct 
formation, and repair. In this investigation, 
BaP–DNA adducts were measured using 
HPLC-F, which provides a measure that is 
specific to BaP adducts. However, we did not 
detect PAH–DNA adducts in > 50% of our 
samples, which limited our power to explore 
this association more thoroughly. Because we 
did not detect the theoretically probable posi-
tive association between PAH or BaP expo-
sure and BaP–DNA adduct formation, we 
were unable to further explore the role that 
methylation plays in this biological pathway 
in our study sample.
Global methylation, as measured in 
this study, represents the overall methyla-
tion state of the genome without indicating 
which genomic positions are methylated. 
This measure can be used as a “first screen” 
to determine whether airborne prenatal PAH 
Figure 2. Global DNA methylation in cord blood 
according to prenatal air PAH exposure (based on 
univariate analyses). “High” and “Low” represent 
the geometric mean methylation (and 95% CIs) 
for those with prenatal concentrations above and 
below the median, respectively. 
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Figure 3. Probability of detectable BaP–DNA adducts as a function of global methylation in cord blood (based 
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exposure levels are high enough to influence 
methylation status. The findings of this inves-
tigation indicate that the levels of prenatal 
PAH exposure experienced by our study 
population were associated with significant 
differences in global DNA methylation, inde-
pendent of maternal age or parity, or child’s 
age or ethnicity.
Several toxicologic studies have suggested 
that benzo[a]pyrene diolepoxide (BPDE), a 
biologically reactive metabolite of PAH, inhib-
its DNA methylation. In one study, BALB/3T3 
mouse cells treated with BPDE (but not BaP) 
had a significant inhibition of global DNA 
methylation (Wilson and Jones 1983). These 
authors hypothesized that this inhibition could 
be due to a variety of mechanisms, includ-
ing the formation of adducts, which could, in 
theory, interfere with methyltransferase activ-
ity (Drahovsky and Morris 1972). In support 
of this theory, a recent study reported that 
develop  mental BaP exposure alters the expres-
sion of glycine N-methyltransferase, an enzyme 
involved in 1-carbon metabolism and the regu-
lation of DNA methylation (Fang et al. 2010). 
In contrast, BaP-treated human breast cancer 
cell lines did not show reduced global methyla-
tion measured using a methyl-acceptor assay, 
but BaP treatment did induce gene-specific 
hypo- and hypermethylation (Sadikovic and 
Rodenhiser 2006). These authors suggested 
that the loss of DNA methylation is likely to 
occur at endogenously hypermethylated regions 
(e.g., genomic repetitive elements).
Relatively few epidemiologic studies have 
examined the effects of exposure to PAHs on 
DNA methylation. One such study explored 
the effects of PAH exposure on global methy-
lation (estimated by measuring the methyla-
tion of LINE-1 and Alu repetitive elements) 
among male, non  smoking coke-oven workers 
and controls in Poland (Pavanello et al. 2009). 
The authors reported that global methylation 
was higher among the coke-oven workers than 
non  exposed controls, whose PAH exposure 
was estimated based on BPDE–DNA adducts 
and 1-hydroxypyrene in urine. This is consis-
tent with our finding that detectable adducts 
were associated with higher global methylation 
levels; however, we observed no association 
between 1-hydroxypyrene levels and global 
methylation in a subset of our study popula-
tion. In contrast with our study, Pavanello 
et al. (2009) reported that PAH metabolites 
and adducts were correlated, which may reflect 
high occupational exposure to PAHs in their 
population of coke-oven workers, whereas our 
participants were exposed to lower levels of 
PAHs in ambient air in an urban setting.
Another study examined whether prenatal 
exposure to tobacco smoke, as well as pas-
sive smoke exposure in childhood and cur-
rent smoking in adulthood, was associated 
with global methylation levels in adult blood 
estimated using a [3H]methyl acceptance 
assay (Terry et al. 2008). The authors reported 
that although prenatal tobacco exposure was 
associated with higher levels of methylation, 
childhood and concurrent smoking was asso-
ciated with lower levels of methylation. In 
our study, neonates exposed prenatally to 
ETS had methylation levels similar to those 
of non  exposed neonates. Consistent with 
our report, Terry et al. (2008) observed an 
inverse association between smoking and 
global methylation when both were assessed 
concurrently in adults. Therefore, it may be 
that concurrent smoke or PAH exposure has 
a more pronounced effect on global methyla-
tion than past exposure. The study by Terry 
et al. (2008) also found lower levels of methy-
lation among blacks compared with whites 
or Hispanics, which is consistent with our 
findings that self-identified African Americans 
had significantly lower methylation levels than 
did Dominicans.
The positive association that we observed 
between global DNA methylation and the 
presence of DNA adducts is consistent with 
previously published literature (Pfeifer 2006; 
Tretyakova et al. 2008; Zhang et al. 2005). It 
has been hypothesized that BPDE preferen-
tially targets methylated CpG sites. A num-
ber of stereochemical mechanisms have been 
proposed to explain this apparent affinity, 
including that methylation alters the reactiv-
ity of the CpG dinucleotides, making them 
more attractive binding sites (Tretyakova et al. 
2008), possibly by altering the hydropho-
bicity (Pirogov et al. 1998) or polarizability 
(Sowers et al. 1987). Studies examining the 
nucleotide location of BPDE adduct forma-
tion along the p53 tumor suppressor gene 
have found a high correlation between adduct 
formation sites [which are mutation hot spots 
(Pfeifer et al. 2002)] and patterns of cytosine 
methylation within the p53 gene (Denissenko 
et al. 1997). In these studies, BPDE-DNA 
adducts preferentially targeted guanines 3´ to 
methylated cytosines, and CpG methylation 
strongly enhanced BPDE adduct formation 
(Chen et al. 1998; Denissenko et al. 1997; 
Tretyakova et al. 2002; Weisenberger and 
Romano 1999). The positive association that 
we observed between methylation and BaP–
DNA adducts was non  specific but consistent 
with the findings of in vitro experiments.
An alternative hypothesis suggests that 
binding of BPDE to DNA encourages 
methyla  tion of DNA by influencing DNA 
methyltransferase activity (Subach et al. 
2006). If correct, then it is also possible that 
the positive association we observed between 
DNA methylation and BaP–DNA adducts 
was due to increased methylation at sites of 
BaP–DNA adducts. However, we could not 
discern the temporal sequence of methylation 
and adduct formation in this study.
Conclusions
In this study we provide evidence that prenatal 
PAH exposure may alter global DNA methyla-
tion and that altered DNA methylation may 
influence BaP–DNA adduct formation. 
Understanding both the ability of environ-
mental chemicals to alter methylation and the 
association between altered methylation and 
the formation of DNA adducts is critical to 
develop strategies to reduce disease risk. Future 
studies that can identify factors that influence 
susceptibility to PAH–DNA adduct formation 
and measure site-specific CpG methylation 
and adduct formation in vivo will improve our 
ability to understand these complex molecular 
relationships and biological pathways.
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